by Pete Celano | Aug 15, 2025 | Uncategorized
Here’s a summary of the JAMA Health Forum research letter titled “Projected Savings From Reducing Low-Value Services in Medicare,” published on August 1, 2025: Key Findings The study conducted a cross-sectional analysis examining 47 identified low-value services...
by Pete Celano | Aug 8, 2025 | Press
Episode 6.10 – “New Approaches to Patient Care: NIT-driven drug choices, Virtual Clinics, Large-Scale Screening” from the podcast Surfing the MASH Tsunami by Roger Green. “LiverRight CEO Brandon Tudor and Chief Medical Officer Alexander Lalos...
by Pete Celano | Aug 5, 2025 | Uncategorized
End stage liver disease (ESLD), also known as the final stage liver failure, is an irreversible liver condition that occurs due to acute liver failure or chronic liver diseases resulting in disruption of hepatic parenchyma (liver cells) and the adjacent structures...
by Pete Celano | Aug 4, 2025 | Uncategorized
This 30 July 2025 Gut article “Thrombospondin‑2 is a performant biomarker of at‑risk MASH and advanced MASH fibrosis in a large multicentre European cohort” is revealing; a snapshot of the future. 🧠 Background & Objective Clinical need exists for non‑invasive,...
by Pete Celano | Jul 27, 2025 | Uncategorized
Here’s a summary of the ContagionLive article “Non‑Targeted Hepatitis C Screening in Emergency Departments Increases Diagnoses” (published July 21, 2025): 🧬 Findings from the DETECT Hep C Trial 1. Study Design & Rationale The DETECT Hep C trial was a large...
